Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione maleic acid salt
AssigneeSmithKline Beecham Corporation
InventorsMichael Sasse, Paul David Blackler, David Lee
Life of this patent
Estimating the term…
Abstract
A hydrate of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt, characterised in that it: (i) comprises water in the range of from 0.2 to 1.1% w/w ; and (ii) provides an infra red spectrum containing peaks at 764 and 579 cm−1; and/or (iii) provides an X-ray powder diffraction (XRPD) pattern substantially as set out in Figure II; a process for the preparation of such a compound, a pharmaceutical composition containing such a compound and the use of such a compound or composition in medicine.
Claims14
A hydrate of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt, characterised in that it:
- (i) comprises water in the range of from 0.2 to 1.1% w/w;
- and
- (ii) provides an infra red spectrum containing peaks at 764 and 579 cm−1;
- and/or
- (iii) provides an X-ray powder diffraction (XRPD) pattern substantially as set out in Figure II.
A process according to claim 11, wherein the aqueous ethanol contains from 2% to 2.5% of water by volume.
A method for the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof, in a human or non-human mammal which comprises administering an effective, non-toxic, amount of Hydrate to a human or non-human mammal in need thereof.
Dependencies are inferred from the claim text.